Avantor, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from TD Cowen maintained a Hold rating on the stock and has a $14.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Hold rating due to a combination of factors impacting Avantor’s performance. The company’s recent third-quarter results were disappointing, with a significant drop in stock value following a weak performance and a lowered outlook for fiscal year 2025. This decline is attributed to both macroeconomic challenges in the Life Science Tools market and specific internal issues such as share loss and operational inefficiencies.
Additionally, the new CEO, Emmanuel Ligner, has just begun to outline his strategy for addressing these challenges, but a comprehensive plan is yet to be detailed. While the company has announced cost-cutting measures and a share buyback program, the full impact of these initiatives remains uncertain. Brennan has adjusted the price target to $14, reflecting a conservative valuation approach, and is awaiting further clarity on the CEO’s strategic direction before considering any change in the rating.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is neutral on the stock.